Literature DB >> 18171681

Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression.

Hongchang Li1, Yun Wang, Xiaoqi Liu.   

Abstract

Plk1 (Polo-like kinase 1) has been documented as a critical regulator of many mitotic events. However, increasing evidence supports the notion that Plk1 might also have functions outside of mitosis. Using biochemical fractionation and RNA interference approaches, we found that Plk1 was required for both G(1)/S and G(2)/M phases and that DNA topoisomerase IIalpha (topoIIalpha) was a potential target for Plk1 in both interphase and mitosis. Plk1 phosphorylates Ser(1337) and Ser(1524) of topoIIalpha. Overexpression of an unphosphorylatable topoIIalpha mutant led to S phase arrest, suggesting that Plk1-associated phosphorylation first occurs in S phase. Moreover, overexpression of the unphosphorylatable topoIIalpha mutant activated the ATM/R-dependent DNA damage checkpoint, probably due to reduced catalytic activity of topoIIalpha, and resulted in accumulation of catenated DNA. Finally, we showed that wild type topoIIalpha, but not the unphosphorylatable mutant, was able to rescue topoIIalpha depletion-induced defects in sister chromatid segregation, indicating that Plk1-associated phosphorylation is essential for the functions of topoIIalpha in mitosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171681     DOI: 10.1074/jbc.M709007200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells.

Authors:  Ruth E Gonzalez; Chang-Uk Lim; Kelly Cole; Christine Hanko Bianchini; Gary P Schools; Brian E Davis; Ikuo Wada; Igor B Roninson; Eugenia V Broude
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

2.  Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Authors:  Adrian G Grozav; Belinda B Willard; Toshiyuki Kozuki; Kenichi Chikamori; Marius A Micluta; Andrei-Jose Petrescu; Michael Kinter; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

Review 3.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

4.  Plk1: unexpected roles in DNA replication.

Authors:  Ranadip Mandal; Klaus Strebhardt
Journal:  Cell Res       Date:  2013-09-17       Impact factor: 25.617

5.  Cell division cycle 6, a mitotic substrate of polo-like kinase 1, regulates chromosomal segregation mediated by cyclin-dependent kinase 1 and separase.

Authors:  Hyungshin Yim; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

6.  Fbxo28 promotes mitotic progression and regulates topoisomerase IIα-dependent DNA decatenation.

Authors:  Anne-Sophie Kratz; Kai T Richter; Yvonne T Schlosser; Miriam Schmitt; Anatoliy Shumilov; Henri-Jacques Delecluse; Ingrid Hoffmann
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

Review 7.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

Review 8.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

9.  PICH and cotargeted Plk1 coordinately maintain prometaphase chromosome arm architecture.

Authors:  Yasuhiro Kurasawa; Li-yuan Yu-Lee
Journal:  Mol Biol Cell       Date:  2010-02-03       Impact factor: 4.138

10.  Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.

Authors:  J J Bower; G F Karaca; Y Zhou; D A Simpson; M Cordeiro-Stone; W K Kaufmann
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.